Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healios KKTSE:4593 -6.25%51 Graham Number is 円23.30 as of Jun. 2026, which is 100% below its 10-year median of 10.86. GuruFocus rates TSE:4593 with a GF Score™ of 51/100 and a GF Value™ of 円43.65 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 261 Biotechnology companies, Healios KK ranks worse than 97.7% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-08-22), the stock price of Healios KK is 円270.00. Healios KK's graham number for the quarter that ended in Jun. 2026 was 円23.30. Therefore, Healios KK's Price to Graham Number ratio for today is 11.59.
The historical rank and industry rank for Healios KK's Graham Number or its related term are showing as below:
TSE:4593'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 10.86 Med: 10.86 Max: 11.59
Current: 11.59
During the past 12 years, the highest Price to Graham Number ratio of Healios KK was 11.59. The lowest was 10.86. And the median was 10.86.
TSE:4593's Price-to-Graham-Number is ranked worse than 97.7% of 261
companies
in the Biotechnology industry
Industry Median: 1.9
vs TSE:4593: 11.59
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Healios KK's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Jun. 2026 )
=
270.00
/
23.30
=
11.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Healios KK Graham Number Related Terms
Healios KK Graham Number Historical Data
* Premium members only.
The historical data trend for Healios KK's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4593 vs VRTX, REGN, RVMD: Graham Number Comparison
For the Biotechnology subindustry, Healios KK's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healios KK Price-to-Graham-Number vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Healios KK's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Healios KK's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healios KK (TSE:4593) has a Graham Number of 円23.30 as of Jun. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Healios KK and its competitors. This is 115% above median its historical median of 10.86. Over the past decade, Healios KK's Graham Number has ranged from 10.86 to 11.59. According to the industry distribution chart, Healios KK ranks #255 out of 261 companies in the Biotechnology industry, placing it in the top 97.7%.
Is Healios KK's Graham Number too high?
Healios KK's current Graham Number of 円23.30 is 115% above median its 10-year median of 10.86. Over the past 10 years, this metric has ranged from a low of 10.86 to a high of 11.59. Based on the distribution chart, Healios KK ranks #255 out of 261 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Healios KK has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's Graham Number compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #255 out of 261 companies for Graham Number. This places Healios KK in the lower half of its industry. The industry median Graham Number is 1.90. Historically, Healios KK's own Graham Number has ranged from 10.86 to 11.59 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Biotechnology company?
The median Graham Number among Biotechnology companies is 1.90, based on 261 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Healios KK and its competitors. For the Biotechnology industry, the median Graham Number is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healios KK's current Graham Number is 円23.30, which is 115% above median its own 10-year median of 10.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (TSE:4593) is currently considered Significantly Overvalued. The stock's GF Value™ is 円43.65, compared to a current price of 円270.00 — trading 518.6% above its estimated fair value. The current Graham Number is 円23.30, which is 115% above median its 10-year median of 10.86. Healios KK's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Healios KK (TSE:4593), the current Graham Number is 円23.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healios KK (TSE:4593) Overvalued in 2026?
Based on GuruFocus' analysis, Healios KK stock appears to be overvalued.
The current stock price of 円270.00 is trading 518.6% above its estimated GF Value™ of 円43.65.
GuruFocus considers Healios KK to be Significantly Overvalued.
Key valuation signals for TSE:4593:
Graham Number: 円23.30 (115% above median its 10-year median of 10.86)
GF Value™: 円43.65 vs. price of 円270.00 (518.6% above fair value)
No single metric tells the full story. See the TSE:4593 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
51GF Score
Get the complete analysis for TSE:4593
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4593 has been successfully added to your 
